As the ETF landscape continues to expand, more and more firms are crossing over significant AUM thresholds. That includes some now-veteran shops with strong, growing rosters, like Amplify ETFs. Amplify recently celebrated its own milestone, crossing $10 billion in AUM. Currently at $10.2 billion, the firm completed a major acquisition earlier this year. It acquired ETF Managers Group, which lifted its AUM above $9 billion.
The Amplify CWP Enhanced Dividend Income ETF (DIVO ), which is the firm’s largest ETF, led the way in AUM growth. Sitting at $3.6 billion in AUM, the fund saw its net AUM rise by more than half a billion over the last six months on net. Charging 56 basis points (bps), DIVO provides income via S&P 500 stocks overlaid with a tactical call-writing strategy. It aims to offer 4-7% annual gross income via dividends and option premiums. DIVO has returned 16% YTD, adding solid performance to its income, per ETF Database data.
Amplify ETFs See ETF AUM Cross $10 Billion in AUM
The Amplify Cybersecurity ETF (HACK ) represents another highlight for the firm, acquired as part of the ETF Managers deal. The strategy has contributed significantly in its own right over the last six months, adding more than $40 million in AUM. It is the first ETF to focus on cybersecurity, investing in software and hardware names. The fund will celebrate its tenth birthday next month. It has returned 16.26% YTD per Database data, beating its ETF Database Category and FactSet segment averages.
A final fund to note from the firm, the Amplify Weight Loss Drug & Treatment ETF (THNR ), offers an intriguing thematic play. The arrival of semaglutide drugs as an anti-obesity treatment via brand names like Ozempic has kickstarted the weight loss space. This fund, which launched in May, charges 59 bps to track the VettaFi Weight Loss Drug Index (THINR).
It looks for drug manufacturers with GLP-1 agonist drugs either launched or in trial with the FDA and firms that enable those manufacturers to produce and distribute the drugs. Biotech could intrigue as a space poised to benefit from rate cuts, with THNR one to watch.
As the landscape continues to change, Amplify’s suite may earn more scrutiny. Above that coveted $10 billion AUM line, its suite continues to grow and can offer some intriguing options looking to 2025.
For more news, information, and analysis, visit VettaFi | ETFDB.
VettaFi LLC (“VettaFi”) is the index provider for THNR, for which it receives an index licensing fee. However, THNR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of THNR.
